REVIEW article
Front. Surg.
Sec. Orthopedic Surgery
This article is part of the Research TopicIncreasing Importance of Patients-generated Real World Data for Healthcare Policy Decisions about Medicinal Products: Volume IIIView all 15 articles
Comparative Efficacy and Safety of Teriparatide Versus Bisphosphonates in Osteoporosis: A Meta-Analysis
Provisionally accepted
- 1Wuhan Union Hospital, Wuhan, China
- 2Wuhan Sports University, Wuhan, Hubei Province, China
- 3Rongjun Hostipal of Hubei，Wuhan, China, Wuhan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: This meta-analysis systematically compared the efficacy and safety of teriparatide and bisphosphonates in treating osteoporosis (OP) to inform optimal treatment strategies. Methods: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar from inception through October 2024. Randomized controlled trials comparing teriparatide and bisphosphonates for OP were included. Primary outcomes included vertebral/non-vertebral fracture risk reduction and lumbar spine/femoral neck bone mineral density (BMD) improvements. Data were analyzed using RevMan 5.3, with dichotomous data assessed via odds ratios (OR) and continuous data via mean differences (MD), both reported with 95% confidence intervals (CI). Results: Thirteen studies involving 4,420 patients were analyzed (six Grade A, four Grade B, three Grade C). Teriparatide significantly reduced vertebral (OR = 0.40, 95% CI = [0.33, 0.49], p < 0.00001) and non-vertebral fracture risks (OR = 0.58, 95% CI = [0.54, 0.70], p < 0.00001) compared to bisphosphonates. At 12 months, teriparatide showed greater improvements in lumbar spine BMD (MD = 2.72, 95% CI = [2.44, 3.00], p < 0.00001) and femoral neck BMD (MD = 1.66, 95% CI = [0.42, 2.90], p = 0.0090). In studies with >18-month follow-ups, teriparatide maintained superior lumbar spine BMD (MD = 4.65, 95% CI = [4.28, 5.03], p < 0.00001) and femoral neck BMD (MD = 1.42, 95% CI = [0.57, 2.26], p = 0.0010) improvements. Adverse event rates were comparable between teriparatide and bisphosphonates (MD = 1.03, 95% CI = [0.88, 1.20], p = 0.73). Conclusion: Teriparatide demonstrated superior efficacy in reducing vertebral/non-vertebral fracture risks and improving BMD in both short-and long-term treatments, with a safety profile comparable to bisphosphonates.
Keywords: Teriparatide, Bisphosphonates, Osteoporosis, vertebral fracture, bone mineral density, Meta-analysis
Received: 24 Feb 2025; Accepted: 24 Nov 2025.
Copyright: © 2025 Jin, Dong, 黄, Wang, He, Shen, Ma, Wang, Shi and Shuai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bo Shuai
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.